Jan 11, 2019 - The spectrum of momentum portfolios have a strong lead among the Forensic Positive and Negative, Value and Anomaly stock portfolios I track from various published research studies.This follows my thes
Jan 11, 2019 - Two new deals to start the year and positive trial presentations at the J.P. Morgan Health Care conference have breathed new life into some of last year's biggest stock losers.
Jan 09, 2019 - Amarin Corporation PLC. (NASDAQ:AMRN) 37th Annual JPMorgan Healthcare Conference January 09, 2019, 12:30 AM ET Company Participants John Thero - President and Chief Executive Officer Conference Call P
Jan 08, 2019 - Last Friday, Amarin announced preliminary 2018 results and 2019 revenue guidance of $350m, which is 16% below consensus estimates of $417m. This seems bearish, but the release seeps with bullishness.T
Jan 07, 2019 - The market managed to post solid gains in the first trading week of 2019, despite a steep decline on Thursday triggered by Apple's downward Q1 revenue guidance.The biotech sector easily outperformed t
Jan 06, 2019 - We wrap up our year-end Marketplace Roundtable series with a look forward, as we compile each of our participating Marketplace authors' best picks for 2019.The categories range from small caps to biot
Dec 10, 2018 - Amarin's equity offering took place at $17.575 per share, resulting in minimal dilution.The dilution would reduce Amarin's upside by 1.4% (assuming a target price of $30 per share before).Vascepa saw
Dec 07, 2018 - Sales reps joining Amarin's team already have the knowledge and expertise needed to successfully turn Vascepa into a global brand.Ireland prohibits takeover defenses such as the poison pill; therefore
Dec 07, 2018 - Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Dec 05, 2018 - Amarin Corporation plc (NASDAQ:AMRN) Citi’s 2018 Global Healthcare Conference December 5, 2018, 02:10 PM ET Executives John Thero - President and Chief Executive Officer Analysts Joel Beatty - Citigro